-$1.06 Earnings Per Share Expected for Audentes Therapeutics Inc (NASDAQ:BOLD) This Quarter
Wall Street analysts expect that Audentes Therapeutics Inc (NASDAQ:BOLD) will post earnings of ($1.06) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Audentes Therapeutics’ earnings, with estimates ranging from ($1.13) to ($0.88). Audentes Therapeutics reported earnings per share of ($0.84) during the same quarter last year, which suggests a negative year over year growth rate of 26.2%. The firm is expected to report its next quarterly earnings results on Wednesday, February 26th.
According to Zacks, analysts expect that Audentes Therapeutics will report full-year earnings of ($4.29) per share for the current year, with EPS estimates ranging from ($4.63) to ($3.97). For the next financial year, analysts forecast that the firm will post earnings of ($4.56) per share, with EPS estimates ranging from ($5.78) to ($3.39). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Audentes Therapeutics.
Audentes Therapeutics (NASDAQ:BOLD) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($1.00) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.07) by $0.07. During the same quarter last year, the company posted ($0.97) earnings per share.
BOLD stock traded up $1.98 during midday trading on Friday, hitting $29.06. The company’s stock had a trading volume of 22,965 shares, compared to its average volume of 334,950. Audentes Therapeutics has a 52-week low of $17.95 and a 52-week high of $41.65. The firm has a market capitalization of $1.24 billion, a P/E ratio of -8.53 and a beta of 1.77. The firm has a 50-day simple moving average of $28.23 and a 200-day simple moving average of $34.39.
In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 20,000 shares of Audentes Therapeutics stock in a transaction on Monday, August 12th. The shares were sold at an average price of $34.04, for a total value of $680,800.00. Following the transaction, the chief executive officer now directly owns 135,368 shares in the company, valued at $4,607,926.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Louis G. Lange sold 10,000 shares of the company’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $32.16, for a total transaction of $321,600.00. Following the transaction, the director now owns 276,044 shares in the company, valued at $8,877,575.04. The disclosure for this sale can be found here. 5.30% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dupont Capital Management Corp acquired a new stake in Audentes Therapeutics during the 2nd quarter valued at $745,000. Prudential Financial Inc. lifted its position in Audentes Therapeutics by 272.3% in the 2nd quarter. Prudential Financial Inc. now owns 78,218 shares of the biotechnology company’s stock valued at $2,961,000 after purchasing an additional 57,210 shares during the last quarter. Altshuler Shaham Ltd bought a new stake in Audentes Therapeutics in the 2nd quarter valued at about $669,000. Voloridge Investment Management LLC acquired a new position in Audentes Therapeutics during the 2nd quarter valued at about $993,000. Finally, Global Endowment Management LP boosted its holdings in shares of Audentes Therapeutics by 14.9% in the second quarter. Global Endowment Management LP now owns 449,965 shares of the biotechnology company’s stock worth $17,036,000 after buying an additional 58,384 shares during the period. 98.44% of the stock is owned by institutional investors and hedge funds.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Read More: What is a support level?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.